Khavinson Peptide Bioregulators: What the Evidence Shows

The “peptide bioregulators” of Vladimir Khavinson, including epitalon, pinealon, vilon and vesugen, rest on a large literature written mostly by one group in St. Petersburg. The headline human results, lower mortality in elderly people, come from animal-tissue extracts, not the synthetic peptides sold online. No independent group has tested the peptides in a controlled human trial that we could find.

Key points

• In our PubMed count, 114 of 187 records on these peptides name Khavinson as an author; 117 sit in three journals [1].
• The mortality findings (a 6-8 year study of 266 people, a 12-year randomized study) used thymalin or epithalamin, tissue extracts. Epitalon is a four-amino-acid synthetic [2][3][14].
• One independent lab reproduced telomerase activation in cultured cells, not in people [10].
• None of these peptides is approved in the US or EU. Russia registers thymalin as a medicine and lists some peptides as supplements [14][20][21].
• Human safety data are close to absent [14].

What the theory proposes

Morozov and Khavinson formulated the concept in 1983, after work at the Kirov Military Medical Academy from 1973. Cells were said to make small regulatory peptides, first extracted from the pineal gland, thymus and other organs. In 1999 Khavinson proposed synthesizing 2-4 amino-acid peptides from the amino-acid composition of those extracts and named them “cytogens” [5].

The proposed mechanism is that short peptides enter the nucleus, bind DNA or histones, and change gene expression [6]. The tests cited are cell-culture microarrays (the review says AEDG changed 98 genes and KE 36), histone-binding assays and molecular modelling. In mice, a five-day cortagen course changed 234 of 15,247 heart transcripts [28]. The group’s own 2021 review concedes “very few studies” exist on peptide-DNA binding [6]. No study we opened links a gene-expression change to a clinical effect in people.

The human studies

We read abstracts; most papers are in Russian or Russian-origin journals.

Study	Design	What it reports
Khavinson & Morozov 2003, Neuro Endocrinol Lett [2]	266 older people, 6-8 years, thymalin or epithalamin vs “control”	1.6- to 2.5-fold lower mortality; blinding not described in abstract
Korkushko et al. 2006, Bull Exp Biol Med [3]	“12-year randomized” study, elderly with coronary disease; epithalamine plus basic therapy vs basic therapy	28% fewer deaths, 2-fold lower cardiovascular mortality. Group sizes and blinding: abstract silent, full text not opened
Korkushko et al. 2011 [4]	39 treated vs 40 controls, 3 years, coronary patients	Slower cardiovascular aging, “significantly lower” mortality. Title says pituitary and “15-year”; abstract says pineal and 3 years
Ivko et al., as summarised by FDA [14]	75 women aged 40-50, mostly night-shift workers; 40 with low melatonin metabolite split to placebo or AEDG, 20 days	Urinary 6-sulfatoxymelatonin rose 1.7-fold. FDA: blinding not specified, short, safety not reported
Kuznik et al. 2006-2007 [26][27]	Vilon added to standard care in type 1 diabetes; sizes not in abstract	Changes in coagulation and immune markers
Meshchaninov et al. 2015 [24]	32 adults aged 41-83; vesugen and pinealon; no control described	“Biological age” scores improved; pro-oxidant activity and lower CD34+ cells also reported
Myakotnykh et al. 2016 [25]	110 people; peptides vs baths, oxygen, massage	Best “biological age” change with both peptides combined

Extract studies report mortality; peptide studies report biomarkers and a composite “biological age”. The 2016 record lists Ekaterinburg affiliations, not Khavinson’s institute; the 2015 record lists none [25][24]. See our pinealon research overview and Huberman claim check for the pinealon papers, and our vilon and vesugen overviews.

An independent 2026 narrative review by US authors found epitalon human evidence limited to “small physiological or biomarker studies” and an older retinitis pigmentosa study, with no adequately powered randomized trial; the authors declared no commercial interest [12]. FDA’s own search found three human epitalon studies: two sublingual night-shift studies and one eye-injection study in retinitis pigmentosa [14].

One group, one set of journals

A PubMed search on 2026-11-08 for epitalon, epithalon, vilon, vesugen, cortagen, cartalax and pinealon, keeping records that name them in title or abstract, left 187. Khavinson is an author on 114 (61%). Bulletin of Experimental Biology and Medicine (56), Advances in Gerontology (53) and Neuro Endocrinol Lett (8) hold 117 [1]. Of the 73 without him, many that we could place by affiliation are Russian or Georgian groups (St. Petersburg, Chita, Rostov, Tbilisi); labs elsewhere are few. These counts depend on PubMed indexing and our name matching.

FDA staff wrote that “most pharmacological studies of epitalon” come from Khavinson’s group [14]. Overlap is not misconduct, but it means the findings were checked mainly by their originators.

Independent replication

• Telomerase. A Brunel University London team (2025) treated breast cancer lines (21NT, BT474) and normal epithelial and fibroblast cells. It reported telomere lengthening through hTERT and telomerase in normal cells and through the ALT pathway in cancer cells [10]. A correction was published 2025-11-15; we did not read what it changed [11].
• Other cell work. Chinese mouse-oocyte work (2022) and a Korean bovine-oocyte study (2025) reported protective effects in vitro [15][16].
• Mice and cancer. A Hebrew University team including Anisimov, a frequent Khavinson co-author, reported fewer malignant tumours and no metastases in treated female mice over 6.5 months [29].
• People. We found no independent replication of the mortality results. ClinicalTrials.gov (2026-11-08) has no trial dedicated to epitalon, vilon, vesugen, pinealon or thymalin. One open-label study registered 2026-10-08, estimating 48 participants, applies a topical serum containing epitalon among four other peptides [31].

The telomerase work

In 2003 Khavinson’s group reported that epitalon induced telomerase expression, enzyme activity and telomere elongation in telomerase-negative human fetal fibroblasts [7]. In 2004 fibroblasts from a 24-week fetus, which had stopped dividing at passage 34, made ten more divisions when treated [8]. A 2019 study of blood lymphocytes from 11 men (5 aged 18-22, 6 aged 49-54) found significant telomere changes in 7: five lengthened, two shortened, in culture [9].

It did not show that telomeres lengthen in people taking epitalon, or that this extends life. FDA’s reviewers noted the mouse tumour studies used one dose, only females and short exposure, and that telomerase activation is a theoretical cancer concern; no two-year carcinogenicity study exists [14]. That is a mechanism-based caution, not an observed harm.

Registered and marketed products

Russia. The RLS drug reference lists Thymalin (Тималин; thymus extract from calves and young cattle, lyophilisate for injection) under registration ЛП-№(005867)-(РГ-RU), holder Samson-Med, registered 2024-06-21, status active [20]. RLS is a commercial reference, not the state register. Khavinson’s group dates the first registration to 1982 [5]. RLS lists Vesugen and Pinealon as dietary supplements (БАД, “additional source of peptides”), without manufacturer or certificate number on the pages; they were updated 2022-08-08 [21][22]. We found no RLS entry for epitalon or vilon and did not search the Ministry of Health medicines register.

Elsewhere. Epitalon is sold online as vials, capsules and sprays, several labelled “research use only” [14]. The post analysed below shows vilon and vesugen vials with that label [32]. A 2015 Belgian public-health institute paper reported epitalon in two illegal pharmaceutical preparations [30]. We did not test products. “Research use only” is a seller’s label; it is not an approval and implies no purity check.

Regulatory status

• United States, as of 2026-11-08. No product is FDA-approved, and epitalon has no USP monograph [14]. The Category 2 page (current 2026-04-22) lists epitalon under withdrawn nominations: “FDA has not identified safety-related information regarding epitalon for the proposed route of administration” [17]. FDA’s staff briefing (2026-05-12) said the criteria weigh against listing it for insomnia [14]. At its 2026-07-24 meeting the advisory committee recommended inclusion, reported as 7-5 with one abstention (RAPS) or 7-4 with one abstention (McDermott) [18][13]. The vote is advisory; FDA’s meeting page held no minutes at its 2026-08-06 update [19], and listing needs rulemaking [13]. We found no later FDA action. Vilon, vesugen, pinealon, thymalin, cortagen and cartalax appear on neither the Category 2 page nor the 503A page (content current 2026-05-14) [17][23].
• EU, UK, Germany. FDA’s briefing states no epitalon product is authorised by the EMA or approved in the UK, Germany and several other countries, and that it is absent from the European and Japanese pharmacopoeias [14]. We did not search the EMA, MHRA or BfArM registers ourselves.
• Orphan status. FDA records an epitalon orphan designation for retinitis pigmentosa (2010-09-02), revoked 2016-01-06 [14].

Risks and unknowns

FDA found no pharmacokinetic data, no adverse-event reports in FAERS through 2025-12-08, and no clinical study designed to assess epitalon safety. It also found no developmental or reproductive toxicity studies [14]. An abstract cited by FDA states “no side effects” in elderly people but gives no numbers [14]. Few reports can mean little use.

The 2015 vesugen and pinealon study recorded pro-oxidant activity and fewer CD34+ blood cells, which its authors read as inhibited blood-cell formation; clinical meaning is unknown [24]. FDA also raised injection-related immunogenicity, aggregation and impurity concerns [14]. We found no studies in pregnancy, children, people with cancer histories or on drug interactions. Unregulated vials add uncertainty about contents.

What the @Hoostethics post claims

On 2026-10-15, @Hoostethics posted a tier list titled “ranking the most cope supplements.” Vilon sits in “pretty cope” (third of five tiers) and vesugen in “somewhat cope” (fifth) [32]. It gives no reasons.

Verdict: could not be verified. A placement is an opinion. Evidence for either peptide is small, mostly uncontrolled and from Russian authors (see table), so no benefit is established; nothing found ranks vilon below vesugen. See our cope-supplements tier-list check.

Two readings of the same evidence

	Sympathetic reader	Skeptical reader
Human data	Randomized, long follow-up, large mortality effects	Abstracts omit sizes and blinding; where described, controls got basic care, not placebo; extracts, not peptides
Authorship	Specialists publishing in a niche field	61% share one author; replication is thin
Telomerase	Independent lab confirmed it in cells	Cell lines only; the same study found ALT activation in cancer cells
Safety	No FAERS reports; mouse tumours reduced	No safety trials; cancer mechanism unaddressed
Regulation	Thymalin registered in Russia	Peptides sold as supplements or “research”

Both fit the facts; they differ on how much single-group results count before outside confirmation.

Frequently asked questions

Is there a 12-year human study of epitalon? No. The 12-year study used epithalamin, a pineal extract, and reported 28% fewer deaths [3]. FDA treats it and epitalon as different substances [14].

Has anyone outside Khavinson’s group confirmed epitalon raises telomerase? A UK lab reported it in cultured cells in 2025 [10]. We found no outside human telomere data.

Are Khavinson peptides approved anywhere? Thymalin is a registered medicine in Russia [20]. Vesugen and pinealon appear there as supplements [21][22]. We found no US or EU approval [14].

Did FDA allow compounding of epitalon? Not as of our check. An advisory committee voted 7-4 (one abstention) on 24 July 2026 to recommend epitalon, but listing requires FDA rulemaking [18][13].

Sources

1. NCBI PubMed, searches for epitalon, epithalon, epithalone, vilon, vesugen, cortagen, cartalax, pinealon, “Ala-Glu-Asp-Gly” (run 2026-11-08; 187 relevant records; author counts computed by us). https://pubmed.ncbi.nlm.nih.gov/
2. Khavinson VKh, Morozov VG, “Peptides of pineal gland and thymus prolong human life,” Neuro Endocrinol Lett (2003). https://pubmed.ncbi.nlm.nih.gov/14523363/
3. Korkushko OV, et al., “Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging,” Bull Exp Biol Med (2006). https://pubmed.ncbi.nlm.nih.gov/17426848/
4. Korkushko OV, et al., “Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up,” Bull Exp Biol Med (2011). https://pubmed.ncbi.nlm.nih.gov/22451889/
5. Khavinson VKh, Kuznik BI, Ryzhak GA, “Peptide bioregulators: a new class of geroprotectors. Message 1,” Advances in Gerontology (2013). https://khavinson.info/assets/files/2013-Khavinson_Kuznik.pdf
6. Khavinson VK, et al., “Peptide Regulation of Gene Expression: A Systematic Review,” Molecules (2021-11-22). https://pubmed.ncbi.nlm.nih.gov/34834147/
7. Khavinson VKh, et al., “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells,” Bull Exp Biol Med (2003). https://pubmed.ncbi.nlm.nih.gov/12937682/
8. Khavinson VKh, et al., “Peptide promotes overcoming of the division limit in human somatic cell,” Bull Exp Biol Med (2004). https://pubmed.ncbi.nlm.nih.gov/15455129/
9. Khavinson VK, et al., “Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes,” Bull Exp Biol Med (2019). https://pubmed.ncbi.nlm.nih.gov/31761987/
10. Al-Dulaimi S, et al., “Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity,” Biogerontology (2025-09-04). https://pubmed.ncbi.nlm.nih.gov/40908429/
11. Al-Dulaimi S, et al., “Correction: Epitalon increases telomere length…” Biogerontology (2025-11-15). https://pubmed.ncbi.nlm.nih.gov/41240216/
12. Jain A, et al., “Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence,” Int J Mol Sci (2026-10-08). https://pubmed.ncbi.nlm.nih.gov/42884164/
13. McDermott Will & Schulte, “PCAC backs majority of peptides in two-day public meeting” (2026-07-27). https://www.mcdermottlaw.com/insights/blogs/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/
14. FDA, “FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: Epitalon-Related Bulk Drug Substances” (dated 2026-05-12; PDF text extracted locally). https://www.fda.gov/media/193345/download
15. Yue X, et al., “Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro,” Aging (2022). https://pubmed.ncbi.nlm.nih.gov/35413689/
16. Ullah S, et al., “Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development,” Life Sci (2025). https://pubmed.ncbi.nlm.nih.gov/39788414/
17. FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” (content current 2026-04-22). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
18. RAPS, “FDA advisory committee backs two more peptides, rejects one for compounding list” (2026-07-24). https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html
19. FDA, “July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee” (page current 2026-08-06). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
20. RLS (rlsnet.ru), “Тималин” registration entry (ЛП-№(005867)-(РГ-RU); last amendment 2025-09-01). https://www.rlsnet.ru/regdoc/timalin-lp-005867-rg-ru-91710
21. RLS, “Везуген” dietary supplement entry (updated 2022-08-08). https://www.rlsnet.ru/baa/vezugen-30388
22. RLS, “Пинеалон” dietary supplement entry (updated 2022-08-08). https://www.rlsnet.ru/baa/pinealon-30390
23. FDA, “Bulk Drug Substances Used in Compounding Under Section 503A of the FDCA” (content current 2026-05-14). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
24. Meshchaninov VN, et al., “Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome in remission,” Adv Gerontol (2015). https://pubmed.ncbi.nlm.nih.gov/26390612/
25. Myakotnykh VS, et al., “Comparative analysis of different methods of geroprotective,” Adv Gerontol (2016). https://pubmed.ncbi.nlm.nih.gov/28539017/
26. Kuznik BI, et al., “Effect of thymomimetic vilon on blood coagulation system and fibrinolysis in diabetes mellitus type 1 patients of different age,” Adv Gerontol (2006). https://pubmed.ncbi.nlm.nih.gov/17152731/
27. Kuznik BI, et al., “Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus,” Adv Gerontol (2007). https://pubmed.ncbi.nlm.nih.gov/18306698/
28. Anisimov SV, Khavinson VKh, Anisimov VN, “Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray,” Neuro Endocrinol Lett (2004). https://pubmed.ncbi.nlm.nih.gov/15159690/
29. Kossoy G, et al., “Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice,” In Vivo (2006). https://pubmed.ncbi.nlm.nih.gov/16634527/
30. Vanhee C, et al., “Identification of the small research tetra peptide Epitalon… in two illegal pharmaceutical preparations,” Drug Test Anal (2015), title and record only. https://pubmed.ncbi.nlm.nih.gov/25535022/
31. ClinicalTrials.gov, NCT07888595 and term searches for epitalon, epithalon, vilon, vesugen, cortagen, cartalax, pinealon, thymalin, epithalamin (run 2026-11-08). https://clinicaltrials.gov/study/NCT07888595
32. @Hoostethics, “ranking the most cope supplements” (2026-10-15), text read through the fxtwitter mirror and the attached image viewed. https://x.com/Hoostethics/status/2110728908735979632

This article is information, not medical advice.